Gabelli Remains a Buy on Exactech

By Jason Carr

In a report released today, Jennie Tsai from Gabelli reiterated a Buy rating on Exactech (NASDAQ: EXAC). The company’s shares opened today at $29.15.

According to, Tsai is a 4-star analyst with an average return of 20.1% and a 78.3% success rate. Tsai covers the Healthcare sector, focusing on stocks such as K2M Group Holdings, Globus Medical, and Abbott Labs.

Exactech has an analyst consensus of Moderate Buy.

The company has a one year high of $31.90 and a one year low of $22.20. Currently, Exactech has an average volume of 27.24K.

Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Exactech, Inc. develops, manufactures, markets, distributes, and sells orthopedic implant devices; related surgical instrumentation; and biologic services to hospitals and physicians. It also engages in the sale and distribution of joint replacement systems.